Interní Med. 2007; 9(1): 32-35

The treatment of secondary hyperparathyroidism in practice

MUDr. František Švára
Interní oddělení Strahov, Všeobecná fakultní nemocnice, Praha

The current opinion o the disorder of calcium metabolism and phosphorus in chronic renal failure is much wider than in the past. The disorder is considered to be multisystemic disease, which most important components besides bone changes itself are associated biochemical deviations in laboratory markers of bone metabolism and presence of vascular and other nonskeletal calcifications. The complex view on the problem resulted in a new term – Bone and mineral disorder in chronic renal disease. Based on results of large mortality studies current treatment does not focus on suppression of hyperparathyroidism. Our goal is to reach and maintain in the long-term optimal values of bone metabolism parameters in the area of mineral balance, mainly values of calcium and phosphates. The ultimate goal is decrease of prevalence (or at least a delay) of vascular calcifications and decrease of cardiovascular morbidity and mortality.

Keywords: Key words: secondary hyperparathyroidism, phosphate binders, vitamin D analogues, calcium mimetics.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Švára F. The treatment of secondary hyperparathyroidism in practice. Interní Med. 2007;9(1):32-35.
Download citation

References

  1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephro 2004; 15: 2208-2218. Go to original source... Go to PubMed...
  2. Block GA, Martin KJ, de Francisco AML, et al. The calcimimetic cinacalcet hydrochloride (AMG 073) for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med 2004; 350: 1516-1525. Go to original source... Go to PubMed...
  3. D'Haese PC, Spasovki GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; (Suppl. 85): S73-S78. Go to original source... Go to PubMed...
  4. Chetrow GM, Burke SK, Raggi P Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients Kidney Int 2002; 62: 245-252. Go to original source... Go to PubMed...
  5. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. Go to original source... Go to PubMed...
  6. Moe SM, Cunningham J, Bommer J, Adler J Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, and Sprague SM Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol. Dial. Transplant., 2005; 20 (10): 2186-2193. Go to original source... Go to PubMed...
  7. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 2006; 69: 1945-1953. Go to original source... Go to PubMed...
  8. National Kidney Foundation. National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in CKD Am J Kidney Dis 2003; 42: 1-201.
  9. Neonakis E, Wheeler MH, Krishnan H, Coles GA, Davies F, Woodhead JS: Results of surgical treatment of renal hyperparathyroidism. Arch Surg 1995; 130: 643-648. Go to original source... Go to PubMed...
  10. Sprague SM, Llach F, Amdahl M, Taccetta C, Batile D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490. Go to original source... Go to PubMed...
  11. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. Go to original source... Go to PubMed...
  12. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Thadhani R. Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study J. Am. Soc. Nephrol., Apr 2005; 16: 1115-1125. Go to original source... Go to PubMed...
  13. Young EW, Albert JA, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa Kbommer J Peira Lport F Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study, Kidney Int 2005; 67: 1179-1187. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.